Compare Revvity Inc (RVTY) vs BlackRock TCP Capital Corp (TCPC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Revvity Inc vs BlackRock TCP Capital Corp — how do they compare? Revvity Inc trades at $154.18 (market cap $16.98B), while BlackRock TCP Capital Corp trades at $4.01 (market cap $337.71M). The key difference: Revvity Inc is far larger — about 50.3× BlackRock TCP Capital Corp's market cap, and BlackRock TCP Capital Corp pays the higher dividend (18.88%). Which is the better fit depends on your goals — on Pluang, investors hold Revvity Inc for 12 Days and BlackRock TCP Capital Corp for 88 Days on average.
| RVTY | TCPC | |
|---|---|---|
Market Cap | $16.98B | $337.71M |
Volume | 1,456,900 | 436,109 |
Sector | Health | Financials |
52-Week High | $157.36 | $6.20 |
52-Week Low | $82.26 | $3.13 |
Typical Hold Time | 12 Days | 88 Days |
Enterprise Value | $19.30B | $1.09B |
Dividend Yield | 0.18% | 18.88% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RVTY trades at $152.16, down 0.94% on the day, but maintains a bullish technical trend with strong moving average signals and support near $149. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 results expected soon. Revenue remains stable around $2.9 billion, though net income margins have softened slightly. Recent news highlights product launches and strategic acquisitions, such as the Human Cell Design deal, to bolster its life sciences portfolio.
The outlook is supported by analyst optimism with a 51.72% buy rating and a consensus price target of $132.13, though the current price trades above this target. Key risks include premium valuation metrics, margin pressures, and exposure to macroeconomic headwinds. The stock's proximity to its 52-week high suggests momentum but warrants caution given rich multiples.
TCPC trades at $4.03, up 2.28% today, with a bullish technical signal from moving averages. The company reported negative revenue and net income for 2025 but beat Q2 2026 earnings expectations. Recent portfolio sales have reduced leverage and prompted a strategic review. Analyst consensus shows 30.77% buy ratings with no sell recommendations.
The outlook remains cautious due to negative profitability metrics and declining revenue trends, though recent strategic moves and technical strength offer potential upside. Key risks include ongoing negative cash flow, class action lawsuits, and execution challenges in the private credit market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →About BlackRock TCP Capital Corp
BlackRock TCP Capital Corp is a finance company specializing in middle-market lending. It aims for high returns through income and capital appreciation while prioritizing principal protection. The company invests in debt securities and earns revenue from interest payments, fees, and some equity appreciation.
Read more on TCPC →
